Blue Cross Blue Shield of Michigan and Oncology Physician Resource have launched an oncology treatment initiative aimed at enhancing the quality of care for patients with certain types of cancer.
Blue Cross Blue Shield of Michigan and Oncology Physician Resource have launched an oncology treatment initiative aimed at enhancing the quality of care for patients with certain types of cancer.
The Michigan Oncology Clinical Treatment Pathways program includes up-to-date clinical guidelines for treating patients with lung, breast and colon cancer, as well as guidelines for supportive care. Supportive care products are used to prevent or treat the adverse side effects that arise as a result of the tumor itself or administration of cancer treatment. The guidelines will be shared with oncologists across Michigan.
“The program was initially introduced in September 2009 at the annual Michigan Society of Hematology and Oncology (MSHO) meeting,” says Tom Simmer, MD, chief medical officer at Blue Cross Blue Shield of Michigan. “Regional workshops are taking place and will include material dissemination and individual Q&A sessions. Additional Web conferences were also made available. The Coordinating Center is also introducing the Pathways Program to Michigan oncologists through in-person meetings, mail distribution of program materials and electronically via a Web portal.”
P4 Healthcare, creators of the P4 Pathways program that serves as the foundation for this initiative, will provide technology, tools, expertise, educational programs and hands-on training for developing, implementing, monitoring and reporting on anything relating to the P4 Pathways program.
“This initiative is part of our Physician Group Incentive Program, a partnership between the Blues and Michigan physicians,” says Simmer. “Oncologists share guidelines, findings and other information through meetings, seminars, and written communication. We expect measurable results about one year after the guideline process is implemented. Over time additional information related to clinical outcomes will be available and communicated to the public.”
In this second part of a two-part podcast episode, Managed Healthcare Executive's Managing Editor Peter Wehrwein spoke with Ceci Connolly and Margaret "Meg" Murray about Medicare Advantage utilization and challenges, highlighting proposed CMS payment cuts and prior authorization issues.
Listen
The Departments of Health and Human Services (HHS), Labor, and the Treasury, released final rules on short-term, limited-duration insurance (STLDI) and independent, non-coordinated excepted benefits coverage, addressing issues related to the low-quality insurance, or "junk insurance" plans.
Read More
In this first part of a two-part podcast episode, Managed Healthcare Executive's Managing Editor Peter Wehrwein kicks off our new podcast series "DC Roundtable," with guests Margaret "Meg" Murray, CEO of the Association of Community Affiliated Plans, and member of MHE's Editorial Advisory Board, and Ceci Connolly, president and CEO of the Alliance of Community Health Plans, for a discussion on healthcare policy issues.
Listen
2024 Emerging Leaders in Healthcare — Submit For a Chance to Be Featured in MHE's August Issue
March 28th 2024MHE Editors are seeking diverse healthcare professionals from different backgrounds and healthcare sectors, with individual interests. Eligible candidates are early or mid-career leaders with less than 10 years of experience. Award winners will enjoy complimentary passes to the PBMI Annual National Meeting in Orlando, Florida, from Sept. 4-6. Additional perks include a feature in our August issue, a subscription to MHE and more!
Read More
Muthiah “Muthu” Vaduganathan Discusses the Role of SGLT2 Inhibitors in Heart Failure Treatment
March 27th 2024Editors of Managed Healthcare Executive spoke with Muthiah “Muthu” Vaduganathan MD, MPH, consultant cardiologist at Brigham and Women's Hospital and a member of faculty at Harvard Medical School, about the evolving treatment landscape for heart failure, emphasizing the use of SGLT2 inhibitors alongside other foundational therapies.
Read More